10/3/23 NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal In
UH3 Award follows the successful completion of an initial NIH/NINDS HEAL UG3 grant for which all pre-clinical milestones were met. This NIH/NINDS HEAL UH3 Award will support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study in patients, undertaken in collaboration with Adolore BioTherapeutics and expected to commence in 2026
7/17/23 Adolore BioTherapeutics Presents Encouraging Preclinical Data at the 2023 ASPN Conference
Data demonstrate preclinical proof-of-concept for rdHSV-based CA8* gene
therapy as a disease-modifying long-acting local anesthetic that has the potential
to replace opioids in chronic osteoarthritis (OA) knee pain management.
Company continues to advance development of rdHSV-CA8* gene-therapy
injected in the knee joint for chronic OA knee pain towards IND
7/5/23 Adolore BioTherapeutics to Participate in the Virtual Investor Summer Spotlight Series
Adolore BioTherapeutics, Inc.(“Adolore” or the “Company”) a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced that Roelof Rongen, CEO and Roy Levitt, MD, Founder and Executive Chairman of Adolore,will participate in the Virtual Investor Summer Spotlight Serieson Tuesday, July 11, 2023 at 4:00 PM ET.
6/27/23 Adolore BioTherapeutics Announces Launch of Social Media Channels
Adolore BioTherapeutics, Inc.(“Adolore” or the “Company”) a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced the launch of its new corporate social media channels. To stay up-to-date with Adolore’s latest news and events, connect with the Company on LinkedIn, Facebook and Twitter.
5/23/23 Adolore BioTherapeutics Enters into Exclusive License Agreement with University of Pittsburg
Adolore BioTherapeutics, Inc.(“Adolore” or the “Company”) a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced it has entered into an exclusive licensing agreement with the University of Pittsburgh (or the “University”) for its intellectual property portfolio entitled, “Non-Toxic Herpes Simplex Virus Vectors for Efficient Gene Delivery Applications and Complementing Cells for their Production.”
5/16/23 Adolore BioTherapeutics Enters Exclusive License Agreement with University of Miami
Adolore BioTherapeutics, Inc.(“Adolore” or the “Company”) a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced it has entered into an exclusive licensing agreement with the University of Miami (or the “University”) for its intellectual property portfolio entitled “Long Acting Local Analgesic” and “Long Acting Local Analgesic Mechanisms.”
2/21/23 Adolore BioTherapeutics to Present at the 4TH Annual NIH HEAL Initiative Meeting
Adolore BioTherapeutics, Inc.(“Adolore” or the “Company”) a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced that Dr. Roy C. Levitt, the Company’s founder, and Executive Chairman, will present at the 4thAnnual NIH HEAL Initiative Investigator Meeting taking place February 21-22, 2023. The NIH HEAL (Helping to End Addiction Long-Term) Initiative is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis from all angles.
1/18/23 Adolore BioTherapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast presentation on Thursday, January 19 th at 10:00 AM ET
1/17/23 Adolore BioTherapeutics Strengthens Management Team and Board of Directors
Mr. Rongen appointed as CEO and member of the Board bringing 30 years of executive
leadership experience and expertise across a number of therapeutic areas
Bolstered expertise on Board of Directors with addition of Dr. Rogers who brings significant
leadership and expertise spanning both public and private sectors in health care and the
biopharmaceutical industry
11/14/22 Adolore BioTherapeutics Invited to Present at the 16th Annual Pain Therapeutics Summit
Company to discuss its next generation, disease-modifying, non-opioid analgesic
gene therapy in development for the treatment of chronic pain.
April 5, 2022 - Dr. Roy Levitt, CEO to present - 3rd Annual NIH HEAL Initiative Investigator meeting
April 5, 2022 – Adolore BioTherapeutics, Inc., (“Company” or “Adolore”), announced today that Dr. Roy C. Levitt, the Company’s founder and Executive Chairman, will present the Company’s gene therapy program for osteoarthritis at the Third Annual NIH HEAL Initiative Investigator Meeting on April 11 and April 12, 2022. Dr. Levitt is one of six hundred NIH HEAL Initiative awardees who will attend this meeting. The NIH HEAL Initiative is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Adolore has two preclinical programs focused on developing an opioid-free gene therapy for two chronic pain indications. Adolore has achieved proof-of-concept in animal models, validating the mechanism of action in osteoarthritis (OA) and neuropathic pain. The HEAL grant awarded by the NIH is funding the OA preclinical development program through to IND. In collaboration with NIH, Adolore has conducted safety studies and generated initial biodistribution data supporting the safety profile of this gene therapy. In addition, Adolore has generated proof-of-concept efficacy data and is developing the CMC and regulatory strategies to be reviewed with FDA at an Interact meeting. The Company also has a rare disease gene therapy program for Erythromelalgia (EM), an orphan indication for which there are no current FDA approved treatments. EM is a rare, heritable, chronic and debilitating pain disease.
12/1/21 Dr. Roy Levitt, Chairman of Adolore BioTherapeutics to Presented at 3rd Annual Gene Therapy
December 1, 2021 – Adolore BioTherapeutics, Inc., (“Company” or “Adolore”), announced today that Dr. Roy C. Levitt, the Company’s founder and Executive Chairman, will present the Company’s gene therapy programs for chronic pain at the 3rd Annual Gene Therapy for Neurological Disorders Conference on December 6, 2021 in Boston. Adolore has two preclinical programs focused on developing an opioid-free gene therapy for two chronic pain indications. Adolore has achieved proof-of-concept in animal models for chronic pain, validating the mechanism of action applicable to numerous causes of chronic pain. The Company’ initial clinical program is anticipated to be for Erythromelalgia (EM), an Orphan indication for which there are no current FDA-approved treatments. EM is a rare, heritable and recurrent life-long debilitating neuropathic pain disease. Adolore is also developing this gene therapy for a second indication, chronic pain associated with moderate-to-severe osteoarthritis of the knee. Adolore is collaborating with two major universities who received a HEAL grant from the NIH to fund the OA preclinical development program through to an in-effect IND.